Why the study?
African swine fever is highly lethal and lacks a credible commercially available vaccine, prompting a comprehensive summary of vaccine development data in China to inform global progress.
This review summarizes the progress of African Swine Fever vaccine development in China from 2018 to 2022, highlighting that further clinical application still requires extensive testing.
Answers are grounded in this paper and cite their sources.
Novel ASF vaccine insights remain hypothesis-generating; prospective trials needed before field consideration.
African swine fever (ASF) is a highly lethal and contagious disease of domestic pigs and wild boars. There is still no credible commercially available vaccine. The only existing one, issued in Vietnam, is actually used in limited quantities in limited areas, for large-scale clinical evaluation. ASF virus is a large complex virus, not inducing full neutralizing antibodies, with multiple genotypes and a lack of comprehensive research on virus infection and immunity. Since it was first reported in China in August 2018, ASF has spread rapidly across the country. To prevent, control, further purify and eradicate ASF, joint scientific and technological research on ASF vaccines has been carried out in China. In the past 4 years (2018-2022), several groups in China have been funded for the research and development of various types of ASF vaccines, achieving marked progress and reaching certain milestones. Here, we have provided a comprehensive and systematic summary of all of the relevant data regarding the current status of the development of ASF vaccines in China to provide a reference for further progress worldwide. At present, the further clinical application of the ASF vaccine still needs a lot of tests and research accumulation.
No takes yet. Share an insight, caveat, or question.
Han et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: